期刊文献+

乳腺癌MCF-7细胞系9p21缺失断点的精确定位分析 被引量:2

Deletion breakpoint mapping on chromosome 9p21 in breast cancer cell line MCF-7
下载PDF
导出
摘要 目的对乳腺癌MCF-7细胞系9p21区缺失断点进行精确定位。方法采用多重连接探针扩增技术(MLPA)检测MCF-7细胞系9p21区缺失断点的大致区间,采用长PCR扩增缺失断点,引物步移缩小缺失断点的所在区间,测序确定缺失断点的位置。结果 MLPA检测探明MCF-7细胞系的端粒侧断点位于MTAP基因内,着丝粒侧断点位于CDKN2A基因内;通过长PCR、引物步移及测序确定在MCF-7细胞系中,缺失位点位于chr9:21819532至chr9:21989622之间,大小为170kb;断点端粒侧位于MTAP基因的内含子4内,着丝粒侧位于CDKN2A(p14)基因的内含子1内近外显子1β处。结论长PCR是缺失断点定位的良好方法。在MCF-7细胞系中,存在一个起于MTAP基因内、止于CDKN2A基因内、大小为170kb的缺失片段,其意义有待进一步研究。 Objective To map the deletion breakpoint of chromosome 9p21 in breast cancer cell line MCF-7.Methods The deletion of chromosome 9p21 was checked by Multiplex Ligation-dependent Probe Amplification(MLPA) in MCF-7. Subsequently,the deletion breakpoint was amplified by long range PCR and the deletion region was narrowed by primer walking. Finally,the deletion position was confirmed by sequencing.Results The deletion was found starting within the MTAP gene and ending within CDKN2A gene by MLPA.Based on long range PCR and primer walking,the deletion was confirmed to cover the region from chr9:21819532 to chr9:21989622 by sequencing,with a deletion size of 170kb,starting within the intron 4 of MTAP and ending within the intron 1 near exon 1β of CDKN2A.Conclusions Long range PCR is an efficient way to detect deletion breakpoints. In MCF-7, the deletion has been confirmed to be 170kb, starting within the MTAP gene and ending within the CDKN2A gene.The significance of the deletion warrants further research.
出处 《解放军医学杂志》 CAS CSCD 北大核心 2012年第5期405-408,共4页 Medical Journal of Chinese People's Liberation Army
关键词 乳腺肿瘤 细胞系 MCF-7 染色体缺失 breast neoplasms cell line MCF-7 chromosome deletion
  • 相关文献

参考文献10

  • 1Sharpless NE. INK4a/ARF: a multifunctional tumor suppressor locus[J]. Mutat Res, 2005, 576(1/2): 22-38.
  • 2Gil J, Peters G. Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all[J]. Nat Rev Mol Cell Biol, 2006, 7(9): 667-677.
  • 3Christopher SA, Diegelman P, Porter CW, et al. Methylthio-adenosine phosphorylase, a gene frequently codeleted with p16(cdkN2a/ARF), acts as a tumor suppressor in a breast cancer cell line[J]. Cancer Res, 2002, 62(22): 6639-6644.
  • 4Novara F, Beri S, Bernardo ME, et al. Different molecular mecha-nisms causing 9p21 deletions in acute lymphoblastic leukemia of childhood[J]. Hum Genet, 2009, 126(4): 511-520.
  • 5Mistry SH, Taylor C, Randerson-Moor JA, et al. Prevalence of 9p21 deletions in UK melanoma families[J]. Genes Chromo-somes Cancer, 2005, 44(3): 292-300.
  • 6Lesueur F, de Lichy M, Barrois M, et al. The contribution of large genomic deletions at the CDKN2A locus to the burden of familial melanoma[J]. Br J Cancer, 2008, 99(2): 364-370.
  • 7Schmid M, Sen M, Rosenbach MD, et al. A methylthioadenosine phosphorylase (MTAP) fusion transcript identifies a new gene on chromosome 9p21 that is frequently deleted in cancer[J]. Oncogene, 2000, 19(50): 5747-5754.
  • 8Liu YT, Carson DA. A novel approach for determining cancer genomic breakpoints in the presence of normal DNA[J]. PLoS One, 2007, 2(4): e380.
  • 9Martin-Harris MH, Bartley PA, Morley AA. Gene walking using sequential hybrid primer polymerase chain reaction[J]. Anal Biochem, 2010, 399(2): 308-310.
  • 10Ochman H, Gerber AS, Hartl DL. Genetic applications of an inverse polymerase chain reaction[J]. Genetics, 1988, 120(3): 621-623.

同被引文献42

  • 1Polyak K. Breast cancer: origins and evolution[J]. J Clin Invest, 2007, 117( 11): 3155-3163.
  • 2Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer[J]. Nat Rev Cancer, 2009, 9(9): 631-643.
  • 3Jordan VC. Tamoxifen (1C146,474) as a targeted therapy to treat and prevent breast cancer[J]. Br J Pharmacol, 2006, 147(Suppl 1): S269-S276.
  • 4Osborne CK, Shou J, Massarweh S, et al. Crosstalk between estrogen receptor and growth factor receptor pathways as a causefor endocrine therapy resistance in breast cancer[J]. Clin Cancer Res, 2005, 11(2 Pt2): 865s-870s.
  • 5Ring A, Dowsett M. Mechanisms of tamoxifen resistance[J]. Endocr Relat Cancer, 2004, 11 (4): 643-668.
  • 6Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer[J]. N Engl J Med, 2004, 350(11): 1081-1092.
  • 7Goss PE, Ingle JN, Martino S, et al. Randomized trial of Letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17[J]. J Natl Cancer Inst, 2005, 97(17): 1262-1271.
  • 8Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after comp|etion of S years' adjuvant treatment for breast cancer[J]. Lancet, 2005, 365(9453): 60-62.
  • 9Chumsri S, Howes T, Bao T, et al. Aromatase, aromatase inhibitors, and breast cancer[J]. J Steroid Biochem Mol Biol, 2011, 12S(1-2): 13-22.
  • 10Vendrell JA, Bieche I, Desmetz C, et al. Molecular changes associated with the agonist activity of hydroxy-tamoxifen and the hyper-response to estradiol in hydroxy-tamoxifen-resistant breast cancer cell lines[J]. Endocr Relat Cancer, 2005, 12(1): 75-92.

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部